

Fig. 2. Time- and angle-dependency of the quantity $Kc/\Delta R(\theta)$, where K is Rayleigh's constant, c fibrinogen concentration and $\Delta R(\theta)$ the excess scattering at angle θ . (□) Extrapolated reciprocal apparent weight-av. M_w at zero angle (cf. [11]). Experimental conditions: 0.5 M NaCl, 0.05 M Tris (pH 7.4) and 20°C. Fibrinogen was 0.556 mg/ml; thrombin act. $15.4 \times 10^{-3} \text{ min}^{-1}$.

demonstrates that hirudin indeed is able to completely inhibit polymerization, as originally observed in [4]. Similar inhibitions have been observed at the lower ionic strengths of 0.35 and 0.15 M.

Parallel to the light-scattering measurements the release of fibrinopeptides A and B was followed by HPLC. To this end, at different reaction times 200 μ l samples were drawn from the reaction mixture in the light-scattering cuvet and heated at 90°C for 2 min to deactivate thrombin and to precipitate fibrinogen and fibrin [7]. After centrifugation, 70 μ l of the supernatant was injected on a 3.9 mm \times 30 cm μ m




Fig. 3. Some typical progress curves for the thrombin-induced polymerization of fibrin. Experimental conditions: 0.5 M NaCl, 0.05 M Tris (pH 7.4). Fibrinogen: (■) 0.803 mg/ml; (●) 0.660 mg/ml; (+) 0.473 mg/ml. Thrombin act.: (■) $3.80 \times 10^{-3} \text{ min}^{-1}$; (●) $18.7 \times 10^{-3} \text{ min}^{-1}$; (+) $35.5 \times 10^{-3} \text{ min}^{-1}$; (†) indicates the moment of hirudin addition.

Bondapak C₁₈ column (Waters Assoc.). Separation of the fibrinopeptides was satisfactory with an eluent consisting of 80% 0.01 M ammonium phosphate (pH 2.90) and 20% acetonitrile [8] at a flow rate of 2 ml/min.

3. Discussion

The finding that hirudin is able to instantly inhibit the polymerization of fibrin implies that under the prevailing experimental conditions the kinetics of the process is completely enzyme-controlled. In [4] it was suggested that at the relatively high ionic strengths as used here, the rate of proteolysis is the rate-determining step in the enzymatic fibrinogen/fibrin conversion. As a consequence, fibrin monomers with just one A-peptide split off, rapidly dimerize with other monofunctional monomers to form a blocked dimer. Dimers in turn can be activated by the splitting off of a further A-peptide to yield the activated, monofunctional dimer. These rapidly form inert trimers and tetramers through associations with other activated monofunctional monomers and dimers, and so on (see fig.1). This reaction scheme does not contradict those proposed in [3,9].

The rate equations for the above reaction scheme read:

$$d[P_1]/dt = -v'[P_1] \quad (1)$$

$$d[P_j]/dt = -v'[P_j] + (k_s/2) \sum_{i=1}^{j-1} [P_{j-i}^*] [P_i^*] \quad (2)$$

$j = 2, 3, 4, \dots$

and

$$d[P_j^*]/dt = v'[P_j] - k_s [P_j^*] \sum_{i=1}^{\infty} [P_i^*] \quad (3)$$

$j = 1, 2, 3, \dots$

where:

$[P_j]$ = the number concentrations of the inert species of the degree of polymerization j ;

$[P_j^*]$ = that of the corresponding monofunctional species;

k_s = a universal association constant.

The factor 1/2 in the second term on the right side of eq. (2) is introduced to avoid double counting of aggregated species [10]. Further, equal substrate properties are accepted for monomeric and polymeric P_j -particles. In agreement with this assumption v' in eq. (1)–(3) is defined by:

$$v' = V_{\max} / \left(K_m + \sum_{j=1}^{\infty} [P_j] \right) \quad (4)$$

with K_m the Michaelis-Menten constant.

The hirudin experiment demonstrates that the polymerization instantly stops after the addition of the inhibitor, and that therefore the concentrations of activated species, $[P_j^*]$, must be vanishingly low. Introducing the steady-state condition $d[P_j^*]/dt = 0$ into eq. (3) then immediately leads to the following set of equations for the rate of change of inert particles:

$$d \sum_{j=1}^{\infty} [P_j] / dt = (v'/2) \sum_{j=1}^{\infty} [P_j] \quad (5)$$

and

$$d[P_j]/dt = -v'[P_j] + (v'/2) \sum_{i=1}^{j-1} [P_{j-i}] [P_i] / \sum_{j=1}^{\infty} [P_j] \quad (6)$$

$j = 2, 3, 4, \dots$

Equation (6) can be integrated to yield:

$$[P_j] / \left(\sum_{j=1}^{\infty} [P_j] \right)^2 = \left(1 - \sum_{j=1}^{\infty} [P_j] / [P_1^0] \right)^{j-1} / [P_1^0] \quad (7)$$

in which $[P_1^0]$ is the number concentration of fibrinogen at the start of the reaction and $\sum_{j=1}^{\infty} [P_j]$ can be calculated from the integrated eq. (5).

The weight-av. M_r is defined by (11):

$$\bar{M}_r = M_1 \sum_{j=1}^{\infty} j^2 [P_j] / \sum_{j=1}^{\infty} j [P_j] \quad (8)$$

where: $M_1 = M_r$ of the monomer

Inserting eq. (7) into eq. (8) and carrying through the summation finally gives:

$$\bar{M}_r / M_1 = (1 + \alpha) / (1 - \alpha) \quad (9)$$




Fig.4. Comparing the progress of the weight-average M_r of polymerizing fibrin to the rate of fibrinopeptide-A release. Experimental conditions: 0.5 M NaCl, 0.05 M Tris (pH 7.4) and 20°C. Fibrinogen: 0.337 mg/ml; thrombin act. $2.17 \times 10^{-3} \text{ min}^{-1}$. (●) $(\bar{M}_r - M_1) / (\bar{M}_r + M_1)$ as measured by light scattering; (■) and (+), release of fibrinopeptide A and B, respectively.

in which α is the degree of fibrinopeptide A release, defined as:

$$\alpha = \sum_{j=1}^{\infty} 2(j-1) [P_j] / 2[P_1^0] \quad (10)$$

Eq. (9) allows the independent measurements of the growth of the weight-av. M_r and the release of fibrinopeptide A to be compared. As fig.4 shows, there is indeed a fair correspondance of the plots of $(\bar{M}_r - M_1) / (\bar{M}_r + M_1)$ (eq. (9)) and the degree of peptide A release as measured by HPLC. This observation gives support to the polymerization scheme originally proposed in [4], this the more so since it is seen that the release of fibrinopeptide B strongly falls behind that of peptide A.

Deviations are currently investigated in terms of fibrinogen/fibrin complex formation, non-ideality effects and the influence of the small release of peptide B on the functionality of the aggregating species.

Acknowledgements

We are indebted to the Netherlands Foundation for Chemical Research (SON) for financial support, to K. J. Slangen for his assistance with the HPLC experiments and to F. Haverkate and W. Nieuwenhuizen from the Gaubius Institute at Leyden for stimulating discussions.

References

- [1] Hantgan, R. R. and Hermans, J. (1979) *J. Biol. Chem.* 254, 11272–11281.
- [2] Steiner, R. F. and Laki, K. (1951) *Arch. Biochem. Biophys.* 34, 24–37.
- [3] Blombäck, B., Hessel, B., Hogg, D. and Therkildsen, L. (1978) *Nature* 275, 501–505.
- [4] Smith, G. F. (1980) *Biochem. J.* 185, 1–11.
- [5] Markwardt, F. (1970) *Methods Enzymol.* 19, 924–932.
- [6] Van Ruyven-Vermeer, I. A. M. and Nieuwenhuizen, W. (1978) *Biochem. J.* 169, 653–658.
- [7] Kehl, M., Lottspeich, F. and Henschen, A. (1981) *Hoppe-Seyler's Z. Physiol. Chem.* 362, 1661–1664.
- [8] Sellers, J. P. and Clark, H. G. (1981) *Thromb. Res.* 23, 91–95.
- [9] Doolittle, R. F. (1981) *Sci. Am.* 245, 92–101.
- [10] Overbeek, J. Th. G. (1952) in: *Colloid Science* (Kruyt, H. R. ed) vol. 1, ch. 7, Elsevier, Amsterdam.
- [11] Tanford, C. (1961) *Physical Chemistry of Macromolecules*, Wiley, New York.